Adverse Event Management

Brain Cancer

Breast Cancer

Disparities in Cancer Care

Drug Safety

Colorectal Cancer

Liver Cancer

Gastric Cancers

Gastrointestinal Cancer

Genetics

Kidney Carcinoma

Bladder Cancer

Prostate Cancer

Genitourinary Cancer

Endometrial Cancer

Cervical Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Leukemia

Multiple Myeloma

Lymphoma

Hematology

Immuno-Oncology

Lung Cancer

Myeloproliferative Neoplasms

Nurse Navigation

Pediatric Cancer

Prevention

Radiation Oncology

Sarcomas

Melanoma

Skin Cancer

Supportive Care

Survivorship

Patients who received pomalidomide, bortezomib, and dexamethasone achieved a median overall survival of 35.6 months compared with 31.6 months among patients treated with bortezomib and dexamethasone. 

PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma

Patients with EGFR-mutated non–small cell lung cancer had a median event-free survival of 30.8 months in the durvalumab arm and 19.6 months in the placebo arm.

Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC

Findings from the PACIFIC-R trial showed that patients with EGFR-mutated non-small cell lung cancer experienced shorter progression-free survival with durvalumab than patients with EGFR-wildtype disease. 

Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups 

Quizartinib plus standard intensive induction and consolidation therapy was associated with longer survival rates in patients with FLT3-ITD–positive acute myeloid leukemia. 

Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML 

News

Latest News

FDA News

Survivorship 

Practice Management

Contributers

Media

Medical World News

Podcasts

Videos

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Cancer Insight Summary Slides

Continuing Education

Resources

Oncology Drug Crash Course

Webinars

Cancer Summary Slides

Subscribe

Partners

Articles

Resistance training and walking can be beneficial for patients with multiple myeloma. 

Ambulation Improves Frailty Scores in Patients With Multiple Myeloma

In a single-center retrospective analysis, the median progression-free survival among patients with multiple myeloma treated with teclistamab was 4.7 months. 

Real-World Experiences With Teclistamab Are Comparable To Clinical Trial Reports

Kate Yeager, PhD, RN

Articles

Latest Conference Coverage